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 i g  h  l  i  g  h  t  s
Ursolic  acid  and  ursocholanic  acid  are  efﬁciently  encapsulated  within  PMPC-PDPA  polymersomes  of spherical  or tubular  morphology.
PMPC-PDPA  polymersomes  spherical  or tubular  morphology  are  found  to enter  into  parkin-mutant  ﬁbroblasts  causing  no deleterious  effects.
ATP  levels  are  increased  in  parkin-mutant  ﬁbroblasts  after incubation  with  ursolic  or ursocholanic  acid  loaded  PMPC-PDPA  polymersomes.
The  efﬁcacy  of ursolic  acid  and  ursochocholanic  acid  loaded  PMPC-PDPA  nanoparticles  is similar  to  DMSO  based  formulations  of the  same  compounds.
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a  b  s  t  r  a  c  t
Mutations  in  parkin  cause  autosomal  recessive  Parkinsonism  and  mitochondrial  defects.  A  recent
drug  screen  identiﬁed  a class  of steroid-like  hydrophobic  compounds  able  to  rescue  mitochon-
drial  function  in parkin-mutant  ﬁbroblasts.  Whilst  these  possess  therapeutic  potential,  the  size
and  high  hydrophobicity  of some  may  limit  their  ability  to penetrate  the  blood-brain  barrier
from systemic  circulation,  something  that  could  be  improved  by  novel  drug  formulations.  In  the
present  study,  the  steroid-like  compounds  Ursolic  Acid  (UA)  and Ursocholanic  Acid (UCA)  were  suc-
cessfully  encapsulated  within  nanoscopic  polymersomes  formed  by  poly(2-(methacryloyloxy)ethyl
phosphorylcholine)–poly(2-di-isopropylamino)ethyl  methacrylate)  (PMPC-PDPA)  and separated  into
spherical  and tubular  morphologies  to assess  the  effects  of  nanoparticle  mediated  delivery  on  drug efﬁ-
cacy.  Following  incubation  with  either  morphology,  parkin-mutant  ﬁbroblasts  demonstrated  time  and
concentration  dependent  increases  in  intracellular  ATP  levels,  resembling  those  resulting  from  treatmentMPC-PDPA with  nascent  UA  and  UCA  formulated  in 0.1%  DMSO,  as used  in the original  drug  screen.  Empty  PMPC-PDPA
polymersomes  did  not  alter  physiological  measures  related  to mitochondrial  function  or induce  cytotox-
icity.  In combination  with  other  techniques  such  as  ligand  functionalisation,  PMPC-PDPA  nanoparticles
of  well-deﬁned  morphology  may  prove  a promising  platform  for tailoring  the  pharmacokinetic  proﬁle
and organ  speciﬁc  bio-distribution  of highly  hydrophobic  compounds.
© 2016  The  Authors.  Published  by  Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the  CC  BYAbbreviations: UA, ursolic acid; UCA, ursocholanic acid; PMPC-PDPA, poly(2-(methac
TP, adenosine tri-phosphate; DMSO, dimethyl-sulfoxide; PD, Parkinson’s disease; UDCA
W,  molecular weight; DHE, dehydroergosterol; DLS, dynamic light scattering; TEM, 
ltration; RCF, relative centrifugal force; RP-HPLC, reverse-phase high performance liq
etector; SD, standard deviation; FBS, foetal bovine serum; MEM,  minimum essential m
ethyl ester, perchlorate; MMP,  mitochondrial membrane potential; LDH, lactate dehydr
PEG-PCL, methoxy-poly(ethylene glycol)–polycaprolactone; Akt, protein kinase B.
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. Introduction
Parkinson’s disease (PD) is one of the most common neu-
odegenerative disorders, the prevalence of which is expected
o increase in the coming years [1]. Clinical strategies currently
ffer symptomatic relief, no therapy to slow disease progression
s presently available. Great efforts have been taken to identify
mall-molecules capable of rectifying the pathogenic processes
mplicated in PD, in the hope of producing a readily administrable
isease modifying therapy.
Mitochondrial dysfunction has been observed in familial and
poradic forms of PD [2,3]. In particular we and others have
escribed mitochondrial dysfunction in ﬁbroblasts derived from
atients with parkin mutations, the most common identiﬁable
ause of early onset, familial PD [4,5]. We  identiﬁed a number
f compounds able to restore mitochondrial function in parkin-
utant patient ﬁbroblasts [6]. Compounds of particular interest
ith structural similarities are Ursolic Acid (UA), Ursocholanic Acid
UCA), and Ursodeoxycholic Acid (UDCA), owing to their efﬁcacy,
vailability, and existing knowledge of their pharmacokinetic pro-
les. In addition, we demonstrated that UCA and UDCA produced
herapeutic effects in parkin knock-down mouse cortical neurons,
nd ﬁbroblasts from patients with G2019S LRRK2 mutations, the
ost common known cause of familial PD and a gene implicated
n sporadic PD [7,8]. Evidence elsewhere has demonstrated neuro-
rotective effects of UA [9,10]. Therefore, these compounds have
herapeutic potential in at least some forms of PD.
However, efﬁcacy in vivo for any given compound depends on
ts ability to reach the target tissue at therapeutically effective con-
entrations. Diseases of the brain are notoriously difﬁcult to treat
wing to the presence of the blood-brain barrier (BBB), a hurdle
hat reportedly 98% of known small molecule therapeutics fail to
ffectively penetrate from systemic circulation [11–13]. Owing to
he high hydrophobicity of both UA and UCA, penetrance across the
BB may  be unfavourable following intravenous or oral adminis-
ration due to poor solubility within blood [13]. Indeed, though UA
as been found in the brains of rats following oral administration,
he percentage distribution here was extremely small even after
everal months of continuous administration [14], notable, given
he side effects that have been associated with excessive UA doses
15,16]. The use of formulations that improve the circulation times
nd/or speciﬁcity for BBB interactions of these compounds, without
odiﬁcation to their existing chemistry are thus desirable.
The use of bio-compatible polymeric nanoparticles as alterna-
ives to existing therapeutic drug formulations has received much
ttention given their synthetic and thus exceptionally tailorable
atures [17–19]. They are formed from amphiphilic block copoly-
ers that self assemble and are held together in water by weak
nteractions, facilitating efﬁcient drug -encapsulation and impor-
antly, -release. Yet the macromolecular nature of their component
olymers makes them non-ergodic, i.e. once formed, a particle does
o not exchange material with its environment, resulting in high
tability. They possess dense outer coronas formed from charge
eutral, water soluble chemistries that reduce interactions with
lasma proteins so improving their circulation half-lives in blood
20,21].
The size and shape of polymeric nanoparticles may  also be mod-
ﬁed for speciﬁc applications, the diameter of spherical particles is
nown to inﬂuence the rate and route of uptake into cells. Particle
orphologies with increased aspect ratio show increased circula-
ion half-lives in blood [22–24]. Shape also modiﬁes nanoparticle
inding afﬁnities, by merit of the different shear stresses more or
ess streamlined particles experience in blood ﬂow and alterationzs
o surface areas that may  effectively interact with a biological sur-
ace. Thus nanoparticles morphology may  be used to enhance the
argeting effects bestowed by the attachment of receptor-speciﬁcLetters 630 (2016) 23–29
ligands to nanoparticles. Finally, in packaging a compound within
a carrier and delivering them to cells as “payloads”, enhancements
to therapeutic efﬁcacy relative to the freely diffused molecule can
be achieved both in vitro and in vivo [26–28].
Polymersomes are the macromolecular analogues to lipo-
somes and indeed have been evaluated for several applications
in drug delivery. Numerous reports have detailed the abil-
ity of Poly(2-(methacryloyloxy)ethylphosphorylcholine)–poly(2-
diisopropylamino)ethyl methacrylate) (PMPC-PDPA) polymer-
somes to enter into a variety of primary and immortalised cells
whilst causing no apparent inﬂammatory responses or cell toxi-
city [29–32]. They have also been shown to encapsulate a range
of hydrophilic and hydrophobic compounds, which then enter the
cell and are released there via the endocytic route of entry and
pH-sensitive disassembly of PMPC-PDPA polymersomes within the
early endosome [30–33]. It has been shown that LRP-1 targeting
polymersomes successfully cross the BBB via transcytosis, wherein
they deliver macromolecular cargoes to cells of the CNS [25]. We
recently described a method to create and purify spherical and
tubular PMPC-PDPA polymersomes, morphologies which demon-
strate distinct biological behaviours that could be exploited for
speciﬁc therapeutic applications, including enhancement of BBB
speciﬁc interactions [22,23,34,35].
Here we describe a proof of concept study in which UA  and UCA
are formulated within spherical and tubular PMPC-PDPA nanopar-
ticles and their interactions with parkin-mutant ﬁbroblasts are
assessed. Should these demonstrate similar or improved thera-
peutic effects in parkin-mutant ﬁbroblasts relative DMSO based
formulations, whilst producing no-deleterious effects to viability
and mitochondrial function, such particles may  prove a promising
platform for tailoring drug bio-distribution such as improved brain
penetrance.
2. Materials and methods
2.1. Small molecules
UA, UCA and cholesterol were all purchased from Sigma-Aldrich
Ltd. at the highest available purity. Dehydroergosterol (DHE) was
purchased from Avanti polar lipids inc. Compounds were dissolved
in ethanol or Dimethyl Sulfoxide (DMSO), for the purposes of
nanoparticle encapsulation and cell culture respectively.
2.2. Block co-polymers
PMPC25-PDPA65 was  synthesised by Dr. N. Warren as previously
described [36] and Rhodamine-6G-PMPC25-PDPA70 by Dr.  J. Mad-
sen as previously described [37].
2.3. Nanoparticle formation, separation and characterisation
Nanoparticles were formed in PBS from thin-ﬁlms of PMPC25-
PDPA65 alone or pre-mixed with UA/UCA using the thin-ﬁlm
rehydration method (TFR), as described elsewhere [34]. Prepa-
rations were designed, assuming total efﬁciency of nanoparticle
formation, to produce solutions containing 1 mM UA or UCA
and 10 mg/mL  PMPC25-PDPA65. The resulting nanoparticles were
puriﬁed by hollow ﬁbre ﬁltration (HFF) (KrosFlo Research IIi,
SpectrumLabs), using a 1 in 100 dilution and a polysulfone
based separation module (500 kDa molecular weight cut-off).
Nanoparticles were then separated into polymersome, tubular
polymersomes, and lyotropic structure fractions by centrifugal
fractionation at 2000 and 15,000 RCF, as previously described [34].
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.4. Dynamic light scattering
Particle size distributions were assessed by dynamic light
cattering (DLS) (Zetasizer nano ZS, Malvern Ltd.) at copolymer
oncentration of 0.25 mg/mL  as previously described [36].
.5. Transmission electron microscopy
Nanoparticles were imaged by Transmission Electron
icroscopy (TEM) (FEI Tecnai G2 Spirit electron microscope)
nd images captured on a Gatan Digital Micrograph at 120 keV.
EM samples were prepared as described elsewhere [36]. Brieﬂy,
anoparticles were applied (1 mg/mLPMPC-PDPA) to glow dis-
harged copper grids (Agar Scientiﬁc) coated with carbon, and
tained with phosphotungstic acid (0.75% w/w).
.6. High performance liquid chromatography
Polymer and encapsulate concentrations were determined by
everse-phase performance liquid chromatography (RP-HPLC).
anoparticle samples were dried under vacuum overnight, and
e-solubilised in a 4:1 mixture of acidiﬁed methanol (Chromasolv,
igma-Aldrich) and Milli-Q ﬁltered water, plus 0.1% Triﬂuoroacetic
cid (TFA). RP-HPLC was performed with a C18 analytical column
phenomenex Jupiter; octadecylsilyl ultra-pure silica, C18, 300◦A,
50 × 4.6 mm,  5 m)  using methanol (0.1% TFA) and Milli-Q ﬁltered
ater (0.1% TFA) as eluents A and B respectively in the following
radient (column temperature 30 ◦C, ﬂow rate 1 mL/min); 0 min
0% eluent B, 5 min  30% eluent B, 12 min  100% eluent B, 22 min
00% eluent B, 23 min  30% eluent B, 28 min  30% eluent B. With use
f standard curves, PMPC-PDPA, DHE and UA concentrations were
etermined by UV detection (205 nm), and UCA concentrations
y evaporative light-scattering detection (ELSD). Work involving
V detection alone was performed on Dionex ultimate 3000 sys-
em (MWD-3000 UV detector), and analysed using Chromeleon
oftware (Dionex). Work requiring ELSD was performed on a Shi-
adzu UFLC XR system (SPD-M20A diode array detector, Alltech
LSD 800), and analysed with Labsolutions LCSolution software
Shimadzu).
.7. Patient details
Punch skin biopsies were taken from three patients with
ompound heterozygous mutations in parkin,  following routine
linical procedures (mean age 35 years old ± 2.46 SD) [4]. Patient
D1 has het202-203delAG(exon2)/hetExon2del, patient PD2 has
et202-203delAG(exon2)/hetExon4del and patient PD3 has c.101-
02delAG(exon1)/c.1289G > A(exon11). These were paired with
ontrol ﬁbroblasts obtained from three healthy controls age and
ex matched (mean age 36.7 years old ±3.21 SD, obtained from the
IGMS Human Genetic Cell Repository at the Coriell Institute for
edical Research: GM08400, GM08402, GM07300)
.8. Cell culture
Primary ﬁbroblast cells were cultured continuously in glu-
ose media (Minimum Essential Medium with 10% FBS, 100 IU/ml
enicillin, 100 g/mL streptomycin, 1 mM sodium pyruvate, 2 mM
-glutamine, 0.1 mM amino acids, 50 g/mL uridine and 1 X MEM
itamins). Control and patient ﬁbroblasts were used between pas-
ages 11 and 14, matched to within one passage of each other.For physiological assays, ﬁbroblasts were grown in glucose
edia for 24 h, then switched into a galactose media (DMEM
ithout glucose, supplemented with 10% FBS, sodium pyruvate
 mM,  penicillin 100 IU/mL, streptomycin 100 g/mL and galactoseLetters 630 (2016) 23–29 25
0.9 mg/mL), as described before [4]. Fibroblasts were cultured in
galactose for 24 h before addition of experimental conditions.
2.9. Intracellular ATP levels
Cellular Adenosine Triphosphate (ATP) levels were measured
using the ATPlite kit (PerkinElmer) as described previously [4].
2.10. LDH release
Cytotoxic induction was assessed using the CytotoxOne homo-
geneous membrane integrity kit (Promega) according to the
manufacturer’s instructions.
2.11. TMRM assay
Mitochondrial membrane potential (MMP)  was assessed using a
TMRM assay adapted for use in a 96 well plate format, as described
elsewhere [4].
2.12. Flow cytometry
Uptake of Rhodamine and/or DHE labelled PMPC-PDPA
nanoparticles was assessed by ﬂow cytometry as previously
described [32,34]. Results show median ﬂuorescent intensities
(MFI) from 10,000 ﬁbroblasts as determined by FSC and SSC gating,
minus autoﬂuorescence as measured in untreated ﬁbroblasts.
2.13. Statistical analysis
Statistical signiﬁcance of single experimental factors was
assessed using one-way ANOVA with Bonferoni corrected multiple
comparisons. Statistical signiﬁcance of two experimental factors
was assessed by two-way ANOVA with Bonferoni corrected multi-
ple comparisons.
3. Results
3.1. Characterisation of drug loaded PMPC-PDPA nanoparticles
Four weeks formation by TFR produced nanoparticle pop-
ulations of mixed morphology [34]. High drug encapsulation
efﬁciencies were seen with little decrease in drug to polymer
ratio following puriﬁcation of free drug from the mixed morpholo-
gies (Table 1), indicating that the majority of both UA and UCA
were successfully incorporated into the polymersomes. Puriﬁed
PMPC25-PDPA65 nanoparticles were centrifugally fractionated to
form separate populations enriched with spherical or tubular poly-
mersomes, henceforth referred to as polymersomes and tubular
polymersomes respectively (Fig. 1). Interestingly, drug-polymer
quantiﬁcation revealed a greater concentration of UA and UCA
relative to PMPC25-PDPA65 present within the tubular fractions
(Table 1), and that the relative proportion of tubular polymersome
increased with UA or UCA load, in keeping with a previous report
[34].
3.2. Vesicular PMPC-PDPA nanoparticles cause no cellular toxicity
Following 48 h incubation with mixed morphology nanoparti-
cles (0, 0.1, 0.5, 1 or 2 mg/mL), parkin-mutant and control ﬁbroblasts
demonstrated no apparent cytotoxicity (Fig. 2A). Furthermore, no
alteration to MMP  (Fig. 2B) or cellular ATP levels (Fig. 2C) were
detected at these concentrations. The previously described defects
in parkin-mutant ﬁbroblast mitochondrial function were also seen
(expressed as %Ctrl1 ± SD, PD1 baseline MMP  = 55.6 ± 11.9, and
ATP = 65.6 ± 4.4) [4]. Similar results were noted in a second set of
26 G. Yealland et al. / Neuroscience Letters 630 (2016) 23–29
Table  1
Encapsulation efﬁciencies of UA and UCA loaded PMPC25-PDPA65 mixed morphology nanoparticles (±SD), pre- and post- puriﬁcation by HFF.
PMPC25-PDPA65 (mg/mL) Drug (mg/mL) Drug encapsulation efﬁciency Drug:PMPC-PDPA (mol/mol)
Initial conc. 10 1000 100 2.12
Pre-HFF  Empty 7.8 ± 0.42 – – –
UA  8 ± 0.71 667.6 ± 4.9 66.7 1.754
UCA 8.6 ± 0.7 703.2 ± 7.1 70.32 1.719
Post-HFF Empty 5.8 ± 0.93 – – –
UA  5.3 ± 0.75 392.7 ± 3.2 39.27 1.549
UCA 5.9 ± 0.24 442.5 ± 4.5 44.25 1.584
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sig. 1. UA and UCA loaded nanoparticles. From left to right, TEM images of polymer
LS  auto-correlation functions and estimated size distribution by intensity from (a
arkin-mutant ﬁbroblasts and matched control (Supp. Fig. 1). Incu-
ation with separated polymersomes or tubular polymersomes
lso had no effect on the cellular ATP levels of control or parkin-
utant ﬁbroblasts (Supp. Fig. 2).
.3. Uptake of nanoparticles into parkin mutant ﬁbroblasts
The kinetics of nanoparticle uptake in ﬁbroblasts was investi-
ated by ﬂow cytometry in three primary parkin-mutant ﬁbroblast
ines plus matching controls, incubated with mixed morphology
anoparticles. A rapid nanoparticle binding step was seen within
he ﬁrst minute of incubation followed by a linear phase of more
radual nanoparticle internalisation over the next 48 h, both of
hich were proportional to nanoparticle concentration (Fig. 2D–F).
o signiﬁcant difference in nanoparticle uptake was  seen between
he ﬁbroblast phenotypes as groups, though a deﬁciency in one
arkin-mutant ﬁbroblast relative to controls was noted.
In order to assess the uptake of separated polymersomes and
ubular polymersomes, as well as their ability to deliver steroid-
ike cargoes, further experiments using separated Rh.6G-labbelled
MPC25-PDPA65 polymersomes and tubular polymersomes loaded
ith dehydroergosterol (DHE), a naturally occurring ﬂuorescent
terol, were performed. Polymersome accumulation into ﬁbrob-and tube fractions (scale bars = 500 nm, mol/mol cargo:copolymer ratios indicated),
ty, (b) UA and (c) UCA loaded nanoparticles.
lasts was greater than that of tubular polymersomes following both
24 and 48 h incubation (Supp. Fig. 3). Polymersomes also deliv-
ered greater DHE loads, however to a much lesser extent than the
entry of the nanoparticles themselves, likely reﬂecting the greater
DHE concentrations found in tubular polymersomes relative to
polymersomes (DHE:PMPC25-PDPA65 mol/mol ratios for tubular
polymersomes = 2.689, for polymersomes = 1.164 respectively).
3.4. Therapeutic efﬁcacy of UA and UCA loaded, vesicular
PMPC-PDPA nanoparticles
The effect of empty and UA/UCA loaded polymersomes and
tubular polymersomes on intracellular ATP levels were assessed in
two sets of matched parkin-mutant and control ﬁbroblasts, follow-
ing 24 and 48 h incubation. Separated morphology nanoparticles
were applied to treat cells with 10, 100 or 1000 nM UA or UCA
or at matching copolymer concentrations of empty nanoparticles.
Equivalent concentrations of UA/UCA dissolved in DMSO were also
tested. Following incubation with UA or UCA loaded nanoparticles,
parkin-mutant ﬁbroblasts showed increases in intracellular ATP
levels similar in magnitude to those induced by DMSO based for-
mulations (Fig. 3 and Supp. Table 1), concentrations of 1000 nM UA
or UCA, signiﬁcant increases in parkin-mutant ﬁbroblast ATP lev-
G. Yealland et al. / Neuroscience Letters 630 (2016) 23–29 27
Fig. 2. PMPC25-PDPA65 nanoparticles of mixed tubular and polymersome morphologies enter, and cause no apparent toxicity to, parkin-mutant ﬁbroblasts. (a) Percentage
LDH  release, (b) cellular ATP levels and (c) MMP  were assessed in a set of age matched parkin-mutant (black) and control (grey) ﬁbroblasts following 48 h incubation with
PMPC25-PDPA65 of nanoparticles of mixed morphology (error bars = SD, n = 3). The uptake kinetics of Rh.6G labelled PMPC25-PDPA65 nanoparticles of mixed morphology was
assessed  by ﬂow cytometry at concentrations of (d) 0.1 (inset shows results on a reduced MFI  scale), (e) 0.5 and (f) 1 mg/mL (mean MFIs from three sets of age matched
parkin-mutant and control ﬁbroblasts shown, error bars = SD, n = 3).
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iig. 3. UA and UCA encapsulated within PMPC25-PDPA65 polymersomes (dotted l
imilar to when dissolved in 0.1% DMSO (solid lines). Control (grey) and matched p
b)  48 h, as well as UCA formulations for (c) 24 and (d) 48 h (error bars = SD, n = 3).ls (p < 0.05) were reached by all three drug formulations, with the
xception of UA/UCA loaded tubular polymersomes following 24 h
ncubation (Supp. Table 1). Tube based formulations appeared lessand tubes (dashed lines), elicit dose dependent increases in ﬁbroblast ATP levels
-mutant ﬁbroblasts (black) were incubated with formulations of UA for (a) 24 andefﬁcacious following 24 h incubation (Fig. 3A, C), and DMSO based
formulations produced larger mean ATP levels, with one exception
(UCA DMSO vs UCA tubular polymersomes following 48 h incuba-
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ion in parkin-mutant ﬁbroblasts p < 0.05) no signiﬁcant differences
etween formulations were detected at either time-point, within
he ﬁbroblast phenotypes. Overall, a signiﬁcant dependence on the
resence of parkin mutations for ATP recovery from baseline within
ach UA and UCA formulations was seen (p < 0.001 in all instances),
s were signiﬁcant effects of UA and UCA formulation concen-
rations within parkin-mutant ﬁbroblast ATP levels (p < 0.001 in
ll instances). Unloaded nanoparticles had no signiﬁcant effect on
broblast ATP levels (Supp. Fig. 2).
. Discussion
Both UA and UCA were efﬁciently encapsulated within vesicular
MPC25-PDPA65 nanoparticles using the TFR methodology. Puriﬁ-
ation by HFF resulted in little change in drug to copolymer ratios
ndicating very little drug escaped encapsulation, likely owing to
he very high hydrophobicity of both UA and UCA. Empty vesic-
lar PMPC25-PDPA65 nanoparticles of mixed morphology were
ound to enter parkin-mutant ﬁbroblasts whilst inducing no appar-
nt changes to cell membrane integrity, mitochondrial membrane
otential or intracellular ATP levels.Separated polymersomes and
ubular polymersomes had no effect on cellular ATP levels. Having
hown no overt deleterious effects to parkin-mutant ﬁbroblast via-
ility or mitochondrial function in the face of existing physiological
efects, PMPC25-PDPA65 nanoparticles show promise as therapeu-
ic vectors for parkin-mutant ﬁbroblasts, and perhaps other cells
ossessing known mitochondrial defects [5,6]
Vesicular PMPC25-PDPA65 nanoparticles entered ﬁbroblasts lin-
arly over 48 h after an initial rapid binding phase, both of which
ere proportional to copolymer concentration. No signiﬁcant dif-
erences in uptake were found between control and parkin-mutant
ells. This is perhaps contradictory to work from Sack and co-
orkers in which parkin-mutant cells demonstrated reduced lipid
ptake as a result of altered class B scavenger receptor expression,
he same class of receptors implicated in the uptake of PMPC-
DPA nanoparticles [27,38]. This may  arise from differences in the
ize, morphology, and chemistry of the particles investigated in
ach study as well as the different cell in which their uptake was
ssessed. In addition, the two studies investigated different parkin
utations: where all cell models tested by Sack and co-workers
ossessed exon 2 mutations in both parkin alleles, only one of the
rimary ﬁbroblast lines used in the present study shared this geno-
ype [38]. These same ﬁbroblasts were also the only to demonstrate
 clear deﬁciency in nanoparticle uptake relative to controls. Since
xon 2 of Parkin has been linked to the regulation of Class B scav-
nger receptors, it may  be that its complete loss of function is
ecessary for reduced lipid and PMPC-PDPA nanoparticle uptake
38,39].
Tubular polymersomes were found to enter into ﬁbroblasts less
eadily than polymersomes, in keeping with studies comparing the
ellular uptake of similar nanoparticle morphologies [22,34,35].
heir ability to deliver steroidal cargo however was more closely
atched. This is likely due to the greater cargo to copolymer ratios
ound in the tubular fraction of PMPC25-PDPA65 nanoparticles,
herein a single tube will hold and deliver a greater cargo con-
entration than an equivalent mass of polymersomes.
Both UA and UCA loaded nanoparticles produced concentra-
ion and time dependent increases in the cellular ATP levels of
arkin-mutant ﬁbroblasts with a similar efﬁcacy to DMSO based
ormulations. Though not signiﬁcant, a lower mean efﬁcacy was
een from tubular polymersomes relative to polymersomes fol-
owing 24 h incubation, which may  be linked to the slower uptake
f tubular polymersomes. This could also result from the at least
artially different routes of entry tubular polymersomes and poly-
ersomes take into the cell [34].Letters 630 (2016) 23–29
While drug encapsulation within nanoparticles has been noted
to decrease drug efﬁcacy in at least one instance [40], the majority
of previous reports show improved drug efﬁcacy when com-
pared to “free drug” formulations. This has been attributed to
nanoparticles’ ability to deliver drug “pay loads” to the cell, tran-
siently creating higher local drug concentrations than could be
achieved by simple diffusion [26,27]. For instance, UA loaded
in methoxy-poly(ethylene glycol)–polycaprolactone (mPEG–PCL)
nanoparticles have shown enhanced cytotoxicity against gastric
and liver cancer cell lines [28,41]. UA nano-suspensions and nano-
crystals have also demonstrated enhanced therapeutic effects over
UA in solution [42,43]. That efﬁcacy was not improved in the
present study may  be attributable to a number of factors, including
the relatively poor uptake of PMPC-PDPA polymersomes in ﬁbrob-
lasts relative to many other cell types and the use of galactose-
instead of glucose- cell media, which results in lowered PMPC-
PDPA polymersome uptake (Supp. Fig. 4) [27,32].
Route of delivery may  also impact on drug efﬁcacy. Co-solvation
in DMSO will allow UA and UCA to interact directly with the cell
membrane, as well as adsorb to serum proteins and tissue cul-
ture plastics. Encapsulation within PMPC-PDPA nanoparticles on
the other hand shields against these extracellular interactions and
results in direct delivery of compounds into the cell. That DMSO
based formulations produced somewhat more marked increases
in mean cellular ATP levels might suggest that, though intracellu-
lar delivery UA and UCA is effective, external interactions with the
cell may  be more efﬁcacious. Our previous work showed that the
rescue effect of DMSO formulated UCA was  mediated via the glu-
cocorticoid receptor and Akt signalling [6], however whether these
pathways are utilised following direct delivery into the cell remains
to be investigated.
The high drug loading and slower internalisation kinetics of
tubular polymersomes may  make these of particular use for
therapeutic applications. In vivo, improvements to a compounds
therapeutic potential when packaged within nanoparticles will
rely, in part, on enhancements to their target speciﬁc delivery.
Tubular morphologies have been shown to experience greater
shear stresses within ﬂuid ﬂow [24,44] and to circulate in the
blood of mice for durations far exceeding any other tested morphol-
ogy [22]. When functionalised with receptor ligands, such particles
also demonstrate greater speciﬁcities to their target tissues in vivo
[23,24]. Discher and co-workers suggested a paradigm which uses
tailored receptor ligands of high and low afﬁnity, and particle mor-
phologies that experience well deﬁned shear stresses in ﬂow, may
allow for highly speciﬁc targeting of particles to endothelial walls,
even where unique receptor targets do not exist, such as is the case
in the BBB [23]. In combination with strategies to facilitate the pas-
sage of nanoparticles across the BBB, such as recently described
for Angiopep-2 functionalised PMPC-PDPA polymersomes, tubular
polymersomes have the potential to enhance the brain speciﬁc bio-
distribution of small, highly hydrophobic cargoes, such as UA and
UCA [25].
5. Conclusion
UA and UCA loaded PMPC25-PDPA65 nanoparticles were suc-
cessfully formed with high encapsulation efﬁciencies, and spherical
or tubular polymersome morphologies isolated from these. Both
demonstrated an ability to increase the cellular ATP levels of parkin-
mutant ﬁbroblasts, similar to DMSO based formulations, without
any apparent cytotoxicity or detriment to mitochondrial function.
Thus encapsulation of UA and UCA in PMPC25-PDPA65 polymer-
somes or tubular polymersomes holds promise for the treatment
of parkin-mutant cells. In combination with other techniques such
as ligand functionalisation, one may  be able to tailor the pharma-
ience 
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